Edwards Lifesciences (NYSE: EW) VP sells 24,000 common shares

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported an open-market sale of 24,000 shares of common stock on February 25, 2026 at a weighted average price of $83.8365 per share. After this sale, he directly owned 21,266.2532 shares. Indirect holdings were updated to 38,900.5862 shares through a 401(k) plan and 121,756 shares held by a trust, reflecting a correction of 13,396 shares that were previously reported as directly held. The sale price reflects multiple trades executed between $83.66 and $83.96.

Insider Trade Summary

Net Seller: 24,000 shares ($2,012,076)

Net Sell 3 txns

Insider BOBO DONALD E JR

Role CVP,Strategy/Corp Development

Sold 24,000 shs ($2.01M)

Type	Security	Shares	Price	Value
Sale	Common Stock	24,000	$83.8365	$2.01M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,266.253 shares (Direct); Common Stock — 38,900.586 shares (Indirect, 401(k))

Footnotes (1)

1. This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held. Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/26/2026 - 07:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S		24,000	D	$83.8365(1)	21,266.2532(2)	D
Common Stock								38,900.5862(3)	I	401(k)
Common Stock								121,756(2)	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

2. Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held.

3. Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Edwards Lifesciences (EW) executive Donald E. Bobo Jr. report in this Form 4?

Donald E. Bobo Jr. reported selling 24,000 shares of Edwards Lifesciences common stock in an open-market transaction at a weighted average price of $83.8365 per share, and updated his direct and indirect share holdings, including shares in a 401(k) plan and a trust.

How many Edwards Lifesciences (EW) shares did Donald E. Bobo Jr. sell and at what price?

He sold 24,000 shares of Edwards Lifesciences common stock in an open-market sale. The weighted average sale price was $83.8365 per share, based on multiple trades executed in a price range between $83.66 and $83.96 during the reported transaction date.

What are Donald E. Bobo Jr.’s direct Edwards Lifesciences (EW) holdings after the reported sale?

After the reported sale, Donald E. Bobo Jr. directly holds 21,266.2532 shares of Edwards Lifesciences common stock. This figure reflects his remaining directly owned position following the 24,000-share open-market sale disclosed for the February 25, 2026 transaction date.

What indirect Edwards Lifesciences (EW) holdings did Donald E. Bobo Jr. report?

He reported indirect ownership of 38,900.5862 shares through the company’s 401(k) plan and 121,756 shares held by a trust. The trust total incorporates a correction of 13,396 shares that were previously reported as directly held rather than as indirectly held by the trust.

What correction to prior Edwards Lifesciences (EW) ownership reporting was disclosed?

The filing states that totals were corrected for 13,396 shares held indirectly by Donald E. Bobo Jr.’s trust, which had previously been reported as directly held. This adjustment changes the classification of those shares from direct ownership to indirect ownership through the trust.

How were the Edwards Lifesciences (EW) sale prices determined in the Form 4 filing?

The reported price of $83.8365 per share is a weighted average for multiple trades. These trades were executed at individual prices ranging from $83.66 to $83.96, and the filer undertook to provide detailed trade information upon request to regulators or security holders.